Articles

Bringing the data for precision medicine

IBM and tranSMART bring tech together for translational work; tranSMART announces merger with i2b2
Written byMel J. Yeates
| 4 min read

BOSTON—The tranSMART Foundation and IBM have announced their collaboration and the general availability of the tranSMART platform version 16.2 on IBM’s Power8 servers. The translational research platform is running on IBM Power8 servers at the tranSMART Foundation’s Center of Excellence at the University of Michigan.

In addition, tranSMART announced in May the completion of its merger with i2b2, to become the i2b2 tranSMART Foundation. The mission of the i2b2 tranSMART Foundation is to enable effective collaboration for precision medicine through the sharing, integration, standardization and analysis of heterogeneous data from healthcare and research through engagement and mobilization of a life sciences-focused open-source, open-data community.

Dr. Keith Elliston, executive director of the i2b2 tranSMART Foundation, said, “We believe that by coming together into one single organization, we can link clinical research and translational research through our open-source platforms and our active community of scientists and technologists to enable and accelerate innovation in precision medicine. We believe that the most viable business model for developing the big data infrastructure needed for precision medicine is the open-source model, and the i2b2 tranSMART Foundation is leading this effort.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Volume 13 - Issue 7 | July 2017

July 2017

July 2017 Issue

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue